These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20380480)

  • 1. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
    Ross LL; Weinberg WG; DeJesus E; Fischl MA; Horton JH; Pappa KA; Lancaster CT; Pakes GE; Smith KY
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):407-17. PubMed ID: 20380480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
    Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
    HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
    Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR;
    AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
    HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
    Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D
    Clin Drug Investig; 2014 Apr; 34(4):287-96. PubMed ID: 24557728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
    Nishijima T; Takano M; Ishisaka M; Komatsu H; Gatanaga H; Kikuchi Y; Endo T; Horiba M; Kaneda S; Uchiumi H; Koibuchi T; Naito T; Yoshida M; Tachikawa N; Ueda M; Yokomaku Y; Fujii T; Higasa S; Takada K; Yamamoto M; Matsushita S; Tateyama M; Tanabe Y; Mitsuya H; Oka S;
    Intern Med; 2013; 52(7):735-44. PubMed ID: 23545667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
    Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
    HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
    Ross LL; Rouse E; Gerondelis P; DeJesus E; Cohen C; Horton J; Ha B; Lanier ER; Elion R;
    J Antimicrob Chemother; 2010 Feb; 65(2):307-15. PubMed ID: 20008905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
    Collier AC; Tierney C; Downey GF; Eshleman SH; Kashuba A; Klingman K; Vergis EN; Pakes GE; Rooney JF; Rinehart A; Mellors JW;
    HIV Clin Trials; 2008; 9(2):91-102. PubMed ID: 18474494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.
    Parks DA; Jennings HC; Taylor CW; Acosta EP
    AIDS; 2007 Jun; 21(10):1373-5. PubMed ID: 17545719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
    Betancor G; Garriga C; Puertas MC; Nevot M; Anta L; Blanco JL; Pérez-Elías MJ; de Mendoza C; Martínez MA; Martinez-Picado J; Menéndez-Arias L; ; Iribarren JA; Caballero E; Ribera E; Llibre JM; Clotet B; Jaén A; Dalmau D; Gatel JM; Peraire J; Vidal F; Vidal C; Riera M; Córdoba J; López Aldeguer J; Galindo MJ; Gutiérrez F; Álvarez M; García F; Pérez-Romero P; Viciana P; Leal M; Palomares JC; Pineda JA; Viciana I; Santos J; Rodríguez P; Gómez Sirvent JL; Gutiérrez C; Moreno S; Pérez-Olmeda M; Alcamí J; Rodríguez C; del Romero J; Cañizares A; Pedreira J; Miralles C; Ocampo A; Morano L; Aguilera A; Garrido C; Manuzza G; Poveda E; Soriano V
    Retrovirology; 2012 Aug; 9():68. PubMed ID: 22889300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
    Lennox JL; Landovitz RJ; Ribaudo HJ; Ofotokun I; Na LH; Godfrey C; Kuritzkes DR; Sagar M; Brown TT; Cohn SE; McComsey GA; Aweeka F; Fichtenbaum CJ; Presti RM; Koletar SL; Haas DW; Patterson KB; Benson CA; Baugh BP; Leavitt RY; Rooney JF; Seekins D; Currier JS;
    Ann Intern Med; 2014 Oct; 161(7):461-71. PubMed ID: 25285539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
    Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
    HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
    Albini L; Cesana BM; Motta D; Focà E; Gotti D; Calabresi A; Izzo I; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Quiros-Roldan E; Manili L; Guaraldi G; Lapadula G; Torti C
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):18-30. PubMed ID: 21992924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.